295 related articles for article (PubMed ID: 24438744)
1. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
Chapman KR; Beeh KM; Beier J; Bateman ED; D'Urzo A; Nutbrown R; Henley M; Chen H; Overend T; D'Andrea P
BMC Pulm Med; 2014 Jan; 14():4. PubMed ID: 24438744
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
6. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
Ismaila AS; Huisman EL; Punekar YS; Karabis A
Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Wedzicha JA; Decramer M; Ficker JH; Niewoehner DE; Sandström T; Taylor AF; D'Andrea P; Arrasate C; Chen H; Banerji D
Lancet Respir Med; 2013 May; 1(3):199-209. PubMed ID: 24429126
[TBL] [Abstract][Full Text] [Related]
10. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
11. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
Kerwin E; Hébert J; Gallagher N; Martin C; Overend T; Alagappan VK; Lu Y; Banerji D
Eur Respir J; 2012 Nov; 40(5):1106-14. PubMed ID: 23060624
[TBL] [Abstract][Full Text] [Related]
13. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
14. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R; Banerji D
Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
[TBL] [Abstract][Full Text] [Related]
16. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
Watz H; Mailänder C; May C; Baier M; Kirsten AM
Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
[TBL] [Abstract][Full Text] [Related]
17. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
19. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
D'Urzo A; Bader G; Shen S; Goyal P; Altman P
NPJ Prim Care Respir Med; 2018 May; 28(1):18. PubMed ID: 29795478
[TBL] [Abstract][Full Text] [Related]
20. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
Frith PA; Thompson PJ; Ratnavadivel R; Chang CL; Bremner P; Day P; Frenzel C; Kurstjens N;
Thorax; 2015 Jun; 70(6):519-27. PubMed ID: 25841237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
